AB InBev's U.S. Beyond Beer Sales Surge in Q2: Can the Momentum Last?

AB InBev’s U.S. Beyond Beer portfolio posted mid-70% revenue growth in Q2 2026, while Cutwater recorded triple-digit growth and was the No. 1 market-share gainer in the U.S. spirits industry. Management cited no significant RTD supply constraints, and Flying Fish expanded into eight markets in the first half of 2026, though rising competition could challenge continued growth. AB InBev shares gained 30% over the past year versus 15.3% for the industry; its 2026 and 2027 EPS growth estimates are 17.4% and 11.8%, respectively, and its Zacks rank is Hold.

Analysis

The investable question is whether RTDs add durable profit dollars, not whether a fast-growing subcategory can post another large percentage increase. The article gives no segment base, organic growth split (including BeatBox), or contribution-margin data; without those, the growth rate cannot yet support a meaningful consolidated earnings upgrade. Distribution reach may accelerate trial, but it can also raise promotion and shelf-placement costs, so revenue momentum need not translate into incremental margins.

Near term, BUD’s year-long outperformance and premium to the cited industry multiple make the bar for further positive surprises higher. Stable estimates suggest this news has not yet produced broad earnings revisions. Over the next 1–3 months, retail depletion, repeat purchase, and price/promotion mix matter more than launches or distribution points. Over 6–18 months, success would be evidence that RTDs expand occasions without simply cannibalizing BUD’s beer brands, and that the acquired portfolio earns returns after marketing and integration costs.

The contrarian risk is that investors extrapolate category growth into group EPS too quickly; conversely, if repeat rates and margins hold, BUD’s distribution advantage could make current category-share gains more durable than smaller brands’ gains. DEO is a possible competitive watch, but the article provides no evidence of direct share losses or comparable RTD exposure. No compelling relative-value trade follows from these facts alone.

Key Decisions for Investors

• Do not chase BUD solely on category growth; keep exposure benchmarked to the broader earnings thesis given the share outperformance and valuation premium.
• Use BUD’s next earnings update as a catalyst check: seek organic growth excluding acquisitions, segment profit or margin disclosure, retail depletion/repeat-rate evidence, and promotional intensity. Treat continued sales growth without profit conversion as a negative signal.
• Watch for a positive revision catalyst only if management demonstrates profitable distribution expansion and sustained consumer pull; that would support adding BUD rather than relying on launch announcements.
• Falsify the constructive thesis if RTD growth decelerates alongside heavier discounting, or if management commentary shows weak profit conversion or material beer cannibalization. Avoid a DEO-versus-BUD pair until comparable category exposure and performance data are available.